From ToxBankWiki

Jump to: navigation, search

Leadscope Id LS-1480
CAS 62-55-5
ChemSpider 2006126
Pathway DBs
Assay DBs
PubChem CID 2723949
ChEMBL 38737
Omics DBs
Open TG-Gate 00017
pKa 0.44
ToxCast Accepted no
Toxic Effect Apoptosis
ToxBank Accepted no

Executive Summary

Summary Information

The table listed below contains a summarized listing of toxic effect information leveraged from the 6th European Framework Programme project LIINTOP. For a complete listing of the Gold Compound evaluation criteria please see the Gold Compound Evaluation and Comments immediately following the summary table below.





Supplier Sigma Aldrich
Summary Hepatotoxic Effects from the LIINTOP FP6 Program
Hepatocellular necrosis.gif Apoptosis.gif Transporter inhibition.gif Cholestatic.gif Steatotic.gif Phospholipidosis.gif Hepatocyte function.gif Mithochondria impairment.gif Oxidative stress.gif DNA synthesis genotoxicity.gif Covalent binding.gif Idiosyncrasia metabolic.gif Idiosyncrasia immune.gif Bioactivation required.gif LIINTOP severity.gif References
+ + +

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]

Gold Compound Evaluation and Comments

The following table is organized into four main sections and provides a detailed assessment by the Gold Compound Working Group for the use of this compound as a standard hepatotoxin. The table's four sections (collapsed by default but will expand when the "show" link is clicked) contains detailed information for the core set of SEURAT compound acceptance criteria.

Standard to Meet Compound Assessment
Criteria Notes
The in vivo therapeutic window is used to estimate an appropriate concentration for in vitro toxicity assays. This in vitro concentration should also be consistent with the exposure implied by pharmacokinetics parameters.
We prefer compounds that require metabolic activation, although standards that are active in themselves will be accepted if they have otherwise valuable properties. We require knowing the active metabolite, and we prefer compounds where the metabolite is stable and can be independently tested in order to verify the mechanism of toxicity as well as of metabolic activation in the test cell line.
Literature data for at least one, but not necessarily all, of the ‘omics datasets is desired. This requirement can be waived in special cases.
The IC50’s for in vitro efficacy and toxicity should be consistent with the therapeutic ratio observed in the clinic. These parameters will be dependent on specific cell type and culture conditions, but differences of more than 30-fold in the in vitro vs. in vivo therapeutic ratios should be considered suspect and carefully justified.
This is not a requirement, but compounds utilized in the EPA testing program can be assumed to have physical properties verified to be suitable for in vitro cellular assays.
Sparing soluble compounds may be assayed for solubility in serum and the percent serum used specified here.
This property will be measured when a sample of compound becomes available.

Proprietary Toxicity Literature Report

Toxicity Report

FDA and Label Information

The following link will display all of the currently approved FDA drug products on the market. The web page will contain a table listing all current products by their respective Tradenames and primary active ingredients. The list is navigable by simply clicking on the product of interest, which will in turn list all of the NDA's and ANDA's associated with that product. From here users can click on a specific NDA or ANDA and see documents that have been submitted for the product that the FDA has made available via their website. The types of documents include approval history, letters, reviews and labels.
FDA Approved Products

This next url will perform a search in the FDA's system for all labels for products that contain "Thioacetamide" as an active ingredient.
FDA Label Search

PubMed references

The following resource link will perform a PubMed query for the terms "Thioacetamide" and "liver toxicity".
Thioacetamide Search

EPA Summary

EPA Summary


  1. Feldmann, G., 2006. Liver apoptosis. Gastroenterol. Clin. Biol. 30, 533–545.
  2. Gomez-Lechon, M.J., O’Connor, E., Castell, J.V., Jover, R., 2002. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol. Sci. 65, 299–308.
  3. Gomez-Lechon, M.J., O’Connor, J.E., Lahoz, A., Castell, J.V., Donato, M.T., 2008. Identification of apoptotic drugs: multiparametric evaluation in cultured hepatocytes. Curr. Med. Chem. 15, 2071–2085.
  4. Gomez-Lechon, M.J., Ponsoda, X., O’Connor, E., Donato, T., Jover, R., Castell, J.V., 2003. Diclofenac induces apoptosis in hepatocytes. Toxicol. in Vitro 17, 675– 680.
  5. Kass, G.E., Macanas-Pirard, P., Lee, P.C., Hinton, R.H., 2003. The role of apoptosis in acetaminophen-induced injury. Ann. NY Acad. Sci. 1010, 557–559.
  6. Ioannides, C., Lewis, D.F., 2004. Cytochromes P450 in the bioactivation of chemicals. Curr. Top. Med. Chem. 4, 1767–1788.
  7. Kang, P., Dalvie, D., Smith, E., Zhou, S., Deese, A., Nieman, J.A., 2008. Bioactivation of flutamide metabolites by human liver microsomes. Drug Metab. Dispos. 36, 1425–1437.
  8. Li, A.P., 2002. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the ‘‘multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142, 7–23.
  9. Park, K., Williams, D.P., Naisbitt, D.J., Kitteringham, N.R., Pirmohamed, M., 2005b. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207, 425–434.
  10. Reddy, M.V., Storer, R.D., Laws, G.M., Armstrong, M.J., Barnum, J.E., Gara, J.P., McKnight, C.G., Skopek, T.R., Sina, J.F., DeLuca, J.G., Galloway, S.M., 2002. Genotoxicity of naturally occurring indolecompounds: correlation between covalentDNAbinding and other genotoxicity tests. Environ. Mol. Mutagen. 40, 1–17.
  11. Criddle, D.N., Gillies, S., Baumgartner-Wilson, H.K., Jaffar, M., Chinje, E.C., Passmore, S., Chvanov, M., Barrow, S., Gerasimenko, O.V., Tepikin, A.V., Sutton, R., Petersen, O.H., 2006. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J. Biol. Chem. 281, 40485–40492.
  12. Hanley, P.J., Ray, J., Brandt, U., Daut, J., 2002. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J. Physiol. 544, 687–693.
  13. Moridani, M.Y., Cheon, S.S., Khan, S., O’Brien, P.J., 2003. Metabolic activation of 3- hydroxyanisole by isolated rat hepatocytes. Chem. Biol. Interact. 142, 317–333.
  14. Pereira, C.V., Moreira, A.C., Pereira, S.P., Machado, N.G., Carvalho, F.S., Sardao, V.A., Oliveira, P.J., 2009. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr. Drug Saf. 4, 34–54.
  15. Sanz, A., Caro, P., Gomez, J., Barja, G., 2006. Testing the vicious cycle theory of mitochondrial ROS production: effects of H2O2 and cumene hydroperoxide treatment on heart mitochondria. J. Bioenerg. Biomembr. 38, 121–127.
  16. Yuan, L., Kaplowitz, N., 2009. Glutathione in liver diseases and hepatotoxicity. Mol. Aspects Med. 30, 29–41.

Calculated/Predicted Properties

Water Solubility Results
pH Sol,mg/ml 3+ 0 3- Graph
2 197.78 32.4 67.6 - Thioacetamide solubility.png
5.5 134.42 - 100 -
6.5 134.4 - 100 -
7.4 134.4 - 100 -
10 134.48 - 99.9 -
Summary Solubility Data
Intrinsic Solubility,mg/ml 134.4015
Intrinsic Solubility,log(S,mol/l) 0.2526
Solubility in Pure Water at pH = 7.45,mg/ml 134.4019
Calculations performed using ACD/PhysChem v 9.14
LogD Results
pH LogD Graph
2 -0.43 Thioacetamide logd.png
5.5 -0.26
6.5 -0.26
7.4 -0.26
10 -0.26
Calculations performed using ACD/PhysChem v 9.14
Single-valued Properties
Property Value Units Error
LogP -0.26 0.19
MW 75.13 -
PSA 58.11 -
FRB 0 -
HDonors 2 -
HAcceptors 1 -
Rule Of 5 0 -
Molar Refractivity 22.14 cm3 0.3
Molar Volume 70.21 cm3 3
Parachor 187.3 cm3 4
Index of Refraction 1.54 0.02
Surface Tension 50.64 dyne/cm 3
Density 1.07 g/cm3 0.06
Polarizability 8.78 10E-24 cm3 0.5
Calculations performed using ACD/PhysChem v 9.14
Property Name Value Units Source
pKa 0.44 SPARC v4.5
Estimated VP 1.8 mm Hg EPI Suite v4.10
Estimated VP 240 Pa EPI Suite v4.10
Estimated Water Solubility 2.22E+05 mg/L EPI Suite v4.10
WATERNT Frag Water Solubility Estimate 1.62E+05 mg/L EPI Suite v4.10
pKa Results
Acidic/Basic Acidic/Basic Aparrent pKa Value Error
3 MA 13.25 0.29
3 MB 1.68 0.5
A = Acidic
B = Basic
MA = Most Acidic
MB = Most Basic
Calculations performed using ACD/PhysChem v 9.14

Authors of this ToxBank wiki page

David Bower, Egon Willighagen, Matthew Clark
Personal tools
Renal Toxins
Special Substances
Undifferentiated Stem Cells
hiPSC Lines
Liver Cell Lines
iPS-derived Cardiomyocytes
Reagents (Growth Factors)
Reagents (Antibodies)
Reagents (Others)
Suppliers (Cells)